MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：0
|
作者：
V. Patel
J. Mansi
S. Ghosh
J. Kwok
M. Burke
D. Reilly
N. Nizarali
C. Sproat
K. Chia
机构：
[1] Dept of Oral Surgery,Department of Oncology
[2] Guys & St Thomas' NHS Foundation Trust,undefined
[3] Fl 23,undefined
[4] Tower Wing,undefined
[5] Great Maze Pond,undefined
[6] London,undefined
[7] SE1 9RT,undefined
[8] Guys & St Thomas' NHS Foundation Trust,undefined
[9] Fl 23,undefined
[10] Tower Wing,undefined
[11] Great Maze Pond,undefined
[12] London,undefined
[13] SE1 9RT,undefined
[14] Sedation and Special Care,undefined
[15] Guys & St Thomas' NHS Foundation Trust,undefined
[16] Fl 23,undefined
[17] Tower Wing,undefined
[18] Great Maze Pond,undefined
[19] London,undefined
[20] SE1 9RT,undefined
来源：
British Dental Journal | 2018年 / 224卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Highlights that bisphosphonates continue to be the most common drug implicated in medication-related osteonecrosis of the jaw.Shows that an additional use of bisphosphonates has been indicated and now a further 20,000 women may be prescribed the medication and be exposed to the risk of jaw necrosis.Suggests the burden of additional dental assessment for these patients will fall upon GDPs.Introduces a new communication idea of the dental alert card which provides a warning to dentists for 'at risk' patients.
引用
收藏
页码：74 / 79
页数：5
相关论文
共 50 条
  • [41] Oral bisphosphonates as adjuvant therapy for operable breast cancer
    Powles, Trevor
    McCroskey, Eugene
    Paterson, Alexander
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6301S - 6304S
  • [42] Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault, Richard L.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 61 - 66
  • [43] The role of bisphosphonates as adjuvant therapy for breast cancer.
    Gralow J.R.
    Current Oncology Reports, 2001, 3 (6) : 506 - 515
  • [44] The role of bisphosphonates in early breast cancer
    Paterson, Alexander H. G.
    ONCOLOGIST, 2006, 11 : 13 - 19
  • [45] Use of Bisphosphonates and Risk of Breast Cancer
    Peter Vestergaard
    Lone Fischer
    Marco Mele
    Leif Mosekilde
    Peer Christiansen
    Calcified Tissue International, 2011, 88 : 255 - 262
  • [46] Use of Bisphosphonates and Risk of Breast Cancer
    Vestergaard, Peter
    Fischer, Lone
    Mele, Marco
    Mosekilde, Leif
    Christiansen, Peer
    CALCIFIED TISSUE INTERNATIONAL, 2011, 88 (04) : 255 - 262
  • [47] Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
    Hadji, P.
    Coleman, R. E.
    Wilson, C.
    Powles, T. J.
    Clezardin, P.
    Aapro, M.
    Costa, L.
    Body, J. -J.
    Markopoulos, C.
    Santini, D.
    Diel, I.
    Di Leo, A.
    Cameron, D.
    Dodwell, D.
    Smith, I.
    Gnant, M.
    Gray, R.
    Harbeck, N.
    Thurlimann, B.
    Untch, M.
    Cortes, J.
    Martin, M.
    Albert, U. -S.
    Conte, P. -F.
    Ejlertsen, B.
    Bergh, J.
    Kaufmann, M.
    Holen, I.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 379 - 390
  • [48] THE RISK OF ISCHEMIC HEART DISEASE WITH ADJUVANT ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER
    Abdel-Qadir, H.
    Fischer, H.
    Fu, L.
    Amir, E.
    Harvey, P.
    Lee, D. S.
    Rochon, P.
    Anderson, G.
    CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (10) : S348 - S348
  • [49] Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer
    Albain, Kathy S.
    BREAST, 2011, 20 : S150 - S152
  • [50] Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer
    Lumachi, Franco
    Santeufemia, Davide A.
    Fadda, Giovanni M.
    Tozzoli, Renato
    Chiara, Giordano B.
    Basso, Stefano M. M.
    MEDICINAL CHEMISTRY, 2016, 12 (03) : 261 - 267
12345